Gujarat Themis Biosyn Reports Q2 FY27 Results and Strategic Acquisitions
Gujarat Themis Biosyn Ltd 路 Investor Presentation 路 16 Nov 2026, 12:02 am
Gujarat Themis Biosyn Reports Q2 FY27 Results and Strategic Acquisitions In Q2 FY27, Gujarat Themis Biosyn posted standalone revenue of INR 47.5 Cr, up 12.1% YoY, while EBITDA dropped 15.3% YoY to INR 17.7 Cr (37.4% margin) and PAT fell 40.6% YoY to INR 8.5 Cr due to initial fermentation facility commissioning costs and financing expenses. H1 FY27 standalone revenue reached INR 91.2 Cr (+16.7% YoY) with EBITDA of INR 38.5 Cr (+10.5% YoY). The company completed the acquisition of MicroBiopharm Japan for JPY 21.5 Bn (~INR 1,300 Cr) and agreed to acquire Sanofi鈥檚 anti-infective portfolio (~EUR 158 Mn).
Original exchange filing (PDF)
More announcements from Gujarat Themis Biosyn Ltd
- Recording of Analysts Meet held on 16.11.2026 路 17 Nov 2026
- Please refer to the attached Analysts Presentation 路 16 Nov 2026
- Please refer to the intimation of resignation of Company Secretary & Compliance Officer. 路 15 Nov 2026
- Please refer to the attachment 路 14 Nov 2026
- Kindly refer to the Un-audited Standalone & Consolidated Financial Results for the quarter and half year ended 30.09.2026 路 14 Nov 2026
- Gujarat Themis Biosyn Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026. 路 14 Nov 2026
- Outcome of the Board Meeting held on 14.11.2026 路 14 Nov 2026
- GUJTHEM : 14-Nov-2026 : The Company has informed the Exchange that a Board meeting to be held on November 04, 2026 has been re-scheduled. Further, the Company has informed the Exchange that the meeting of the Board of Directors of the Company will be held on November 14, 2026, To consider and approve the financial results for the period ended September 30, 2026 and other business matters 路 14 Nov 2026
